

Supplementary Materials: Oral Gene Therapy of HFD-obesity *via* Nonpathogenic Yeast Microcapsules Mediated shRNA Delivery

Li Zhang, Wan Zhang, Hang Peng, Yankun Li, Tongtong Leng, Chenxi Xie and Long Zhang

Table S1. The sequences of *IL-1 β* shRNA and its target sites.

| shRNA Name | Sequence (5' to 3') | Target Site (5' to 3') |
|---------------------------------------|---|-------------------------|
| <i>IL-1β</i> shRNA 1 | GACAGAATATCAACCAACA ATAG GTGAAGCCACAGAT GTAT TG TTGGTTGATATTCTGT | ATGGACAGAATATC AACCA |
| <i>IL-1β</i> shRNA 2 | CACATTCTGTTCAAAGAGAG TAG GTGAAGCCACAGAT GTACT TCT CTTTGAACAGAATGTG | TGGCACATTCTGTT CAAAG |
| <i>IL-1β</i> shRNA 3 | CATTGAAGCTGAGAATAAA TTAG GTGAAGCCACAGAT GTAA TT TATTCTCAGCTTCAATG | TTTCATTGAAGCTG AGAAT |

Notes: **Bold** sequence refers to the functional sequence of shRNA and *italic* sequence refers to the loop structure of shRNA.

Table S2. Average net weight gain per week (g).

| | week 1 | week 2 | week 3 | week 4 | week 5 |
|--------------------------|--------|--------|--------|--------|--------|
| NCD (<i>n</i> = 5) | 0 | -5.90 | -1.38 | -0.14 | -0.40 |
| HFD-Ctrl (<i>n</i> = 5) | 0 | -0.02 | 0.94 | 1.74 | 2.19 |
| HFD-Exp (<i>n</i> = 7) | 0 | -1.91 | -1.51 | -1.03 | -0.11 |




Figure S1. Information of shRNA expression vector and efficiency detection of *IL-1 β* shRNA in 293T cells in vitro. **(A)** The shRNA target sites and target sequences (Ts) on the *IL-1 β* mRNA. **(B)** The structure of pRP-CMV-IL1 β -GFP (pRP) and pIN-hU6-shRNA plasmid. **(C)** Functional detection of *IL-1 β* shRNA in 293T cells ($n = 3$). **(D)** Fluorescence intensity. Data was expressed as mean \pm SD. NS (no significance), *** $P < 0.001$.




Figure S2. *IL-1β* shRNA increased lipid metabolism in adipocytes. The function of *IL-1β* shRNA on inhibition of fat expression was evaluated by Oil-Red O Staining and RT-qPCR. (A) Oil-Red O Staining and oil drop area. (B) Percentage of oil drop area. (C–D) Expression of fat related genes *IL-1β* and *FAS*. NS (no significance). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ ($n = 4$).




Figure S3. Oral administration of *IL-1 β* shRNA/yeast inhibits lung *IL-1β* expression. Immunofluorescence staining of *IL-1β* (red) in the lung tissue. DAPI nuclear staining (blue) was also conducted ($n = 4$).




Figure S4. *IL-1 β* shRNA/yeast has no effect on myosin heavy chain and myostatin (MSTN) expression in muscle. The expression of MHC (A) and MSTN (B) in muscle. Data was expressed as mean \pm SD. NS (no significance) ($n = 4$).




Figure S5. Inhibition of weight gain alleviated articular cartilage injury. (A) Safranin O/Fast Green and immunohistochemistry staining of knee joint. (B) Articular cartilage damage scores of the medial tibial plateau (MTP) and medial femoral condyle (MFC) were assessed using OARSI criteria ($n = 15$). (C) Related gene expression of cartilage formation or degradation in the knee joint ($n = 4$). NS (no significance). * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.